Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cardiol Therapeutics(CRDL) the EBIT is -5.589 M (+0.25%), Beat estimate;the EPS is -0.0352 (+51.77%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B0.25%
-0.01B25.25%
+0.00B25.50%
EPSExceed expectations
-0.035251.77%
-0.06816.75%
+0.032945.02%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf